LA JOLLA—For years, the brain has been thought of as a biological computer that processes information through traditional circuits, whereby data zips straight from one cell to another. While that model is still accurate, a new study led by Salk Professor Thomas Albright and Staff Scientist Sergei Gepshtein shows that there’s also a second, very different way that the brain parses information: through the interactions of waves of neural activity. The findings, published in Science Advances on April 22, 2022, help researchers better understand how the brain processes information.
LA JOLLA—Every day, your pancreas produces about one cup of digestive juices, a mixture of molecules that can break down the food you eat. But if these powerful molecules become activated before they make their way to the gut, they can damage the pancreas itself—digesting the very cells that created them, leading to the painful inflammation known as pancreatitis, and predisposing a person to pancreatic cancer.
LA JOLLA—Ursula Bellugi, Distinguished Professor Emerita and Founder’s Chair at the Salk Institute, 2008 inductee to the National Academy of Sciences and winner of the Jacob Javits Neuroscience Investigator Award, died peacefully on April 17, 2022, in La Jolla, CA, at the age of 91.
LA JOLLA—When mice with atopic dermatitis—a common type of allergic skin inflammation—are treated with drugs that target the immune system, their thickened, itchy skin generally heals quickly. But scientists have now discovered that the same treatment in obese mice makes their skin worse, instead. That is because obesity changes the molecular underpinnings of allergic inflammation, both in mice and humans.
LA JOLLA—The Salk Institute mourns the loss of Richard “Rich” Murphy, who died March 24, 2022, in La Quinta, California at the age of 77. Murphy served as the Institute’s president and CEO from 2000 to 2007.
LA JOLLA—Salk Institute Professor Tony Hunter will receive the 2022 American Association for Cancer Research (AACR) Award for Lifetime Achievement in Cancer Research at the April annual meeting of AACR, the largest cancer research organization in the world dedicated to preventing and curing all cancers. This major award is a significant recognition of Hunter’s contributions to cancer research, which have led to the development of the highly effective leukemia drug GleevecTM.
LA JOLLA—The Salk Institute announced today the appointment of Sue Bacino as Vice President of Human Resources (HR) to advance the overall mission of Salk through the acquisition, retention and support of a diverse, world-class faculty and staff.
LA JOLLA—If you’re reaching for the last piece of pizza at a party and see another hand going for it at the same time, your next move probably depends both on how you feel and whom the hand belongs to. Your little sister—you might go ahead and grab the pizza. Your boss—you’re probably more likely to step back and give up the slice. But if you’re hungry and feeling particularly confident, you might go for it.
LA JOLLA—Professors Reuben Shaw, Susan Kaech, Christian Metallo and Alan Saghatelian have received a 2022 Mark Foundation for Cancer Research Endeavor Award to support their research exploring the metabolic changes that help lung cancers develop. The $3 million Endeavor Award promotes collaborative science to tackle some of the toughest challenges in cancer research. The Salk team—one of four teams chosen out of nearly 200 applications submitted by institutions around the world—hopes their work will lead to the development of more effective lung cancer treatments.
LA JOLLA—Salk Institute researchers have developed a new genomic technology to simultaneously analyze the DNA, RNA and chromatin—a combination of DNA and protein—from a single cell. The method, which took five years to develop, is an important step forward for large collaborations where multiple teams are working simultaneously to classify thousands of new cell types. The new technology, published in Cell Genomics on March 9, 2022, will help streamline analyses.
LA JOLLA—Age may be just a number, but it’s a number that often carries unwanted side effects, from brittle bones and weaker muscles to increased risks of cardiovascular disease and cancer. Now, scientists at the Salk Institute, in collaboration with Genentech, a member of the Roche group, have shown that they can safely and effectively reverse the aging process in middle-aged and elderly mice by partially resetting their cells to more youthful states. The study was published in Nature Aging on March 7, 2022.
LA JOLLA—How does an animal make decisions? Scientists have spent decades trying to answer this question by focusing on the cells and connections of the brain that might be involved. Salk scientists are taking a different approach—analyzing behavior, not neurons. They were surprised to find that worms can take multiple factors into account and choose between two different actions, despite having only 302 neurons compared to approximately 86 billion in humans.
LA JOLLA—Salk Institute Professor Martyn Goulding will receive the 2022 Brain Prize for pioneering research on the neuronal circuits that control movement, the Lundbeck Foundation announced today.
LA JOLLA—The Salk Institute mourns the loss of Paul Farmer, MD, PhD, a champion of global health equity and recipient of the inaugural Salk Institute Medal for Health and Humanity in 2005 (now known as the Salk Medal for Public Service). Farmer died in his sleep in Rwanda on February 21. He was co-founder and chief strategist of Partners In Health, an international non-profit organization that provides health care, infrastructure and advocacy for the communities that need it most. He was also professor of medicine at Harvard Medical School and chief of the Division of Global Health Equity at Brigham and Women’s Hospital.
LA JOLLA—The Salk Institute announced today the appointment of David Lawrence to the position of executive director of the Harnessing Plants Initiative (HPI). In his new role, Lawrence will oversee program management and administrative support for the project, as well as help deliver real-world applications based on Salk research findings. For example, he will help scale and deploy Salk Ideal Plants™ worldwide—crops that can capture excess carbon dioxide from the atmosphere and store it deep in root systems.
LA JOLLA/NEW YORK—The Lustgarten Foundation and Salk Institute today announced a new strategic partnership supported by a $5 million grant and focused on identifying and validating potential targets for new pancreatic cancer drugs. The effort will be led by four co-principal investigators, all prominent cancer researchers in the Salk Dedicated Program in Pancreatic Cancer: Professors Reuben Shaw, Ronald Evans, Tony Hunter and Assistant Professor Dannielle Engle. The partnership is part of the Lustgarten Advancing Breakthrough Science (LABS) Program.
LA JOLLA—Salk scientists have engineered mammalian cells to be activated using ultrasound. The method, which the team used to activate human cells in a dish and brain cells inside living mice, paves the way toward non-invasive versions of deep brain stimulation, pacemakers and insulin pumps. The findings were published in Nature Communications on February 9, 2022.
LA JOLLA—Marna C. Whittington, the former CEO of Allianz Global Investors Capital, was elected as chair of the Salk Institute’s Board of Trustees on November 12, 2021. Whittington replaces Daniel C. Lewis, former president of the global commercial management-consulting firm Booz Allen Hamilton.
LA JOLLA—Salk Professor Samuel Pfaff has been named a 2021 Fellow of the American Association for the Advancement of Science (AAAS), the world’s largest general scientific society and publisher of the journal Science. Pfaff is among 564 new AAAS Fellows spanning 24 scientific disciplines who were nominated by their peers for their distinguished efforts to advance science.
LA JOLLA—Decades of research on medical cannabis has focused on the compounds THC and CBD in clinical applications. But less is known about the therapeutic properties of cannabinol (CBN). Now, a new study by Salk scientists shows how CBN can protect nerve cells from oxidative damage, a major pathway to cell death. The findings, published online January 6, 2022, in the journal Free Radical Biology and Medicine, suggest CBN has the potential for treating age-related neurodegenerative diseases, like Alzheimer’s.
Your partnership allows our scientists to accelerate the pace of high-risk, high-reward discoveries that have the potential to benefit the health of all humanity-be it cancer, Alzheimer’s disease, climate change, infectious diseases or more.
